Breast Cancer Clinical Trial
RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma
Summary
RATIONALE: Monoclonal antibodies, such as RAV12, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them.
PURPOSE: This phase I trial is studying the side effects and best dose of RAV12 in treating patients with metastatic or recurrent adenocarcinoma.
Full Description
OBJECTIVES:
Determine the maximum tolerated dose of RAV12 in patients with metastatic or recurrent adenocarcinoma.
Determine the toxicity profile of this drug in these patients.
Determine the pharmacokinetics and immunogenicity of this drug in these patients.
Determine, preliminarily, the antitumor activity of this drug in these patients.
OUTLINE: This is an open-label, dose-escalation study.
Patients receive RAV12 IV over 2 hours 2-3 times per week in weeks 1-4 (course 1). Patients are evaluated for response on day 43. Patients achieving a partial or complete response may be eligible to receive additional courses of RAV12 as above. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of RAV12 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Up to 15 additional patients are treated at the MTD in 1 or more patients groups (e.g., colorectal, pancreatic, gastroesophageal, and other adenocarcinoma).
After completion of study treatment, patients are followed within 4 weeks and then every 6-12 months thereafter.
PROJECTED ACCRUAL: A total of 75 patients will be accrued for this study.
Eligibility Criteria
DISEASE CHARACTERISTICS:
Histologically confirmed adenocarcinoma
Metastatic or recurrent disease
Not curable by standard therapies
Must have failed at least 1, but no more than 3, prior therapies for metastatic or recurrent disease
Patients with colorectal or breast adenocarcinoma must have failed at least 2 prior therapies
Must have had at least stable disease for 3 months while on last treatment prior to most recent disease progression
Meets 1 of the following criteria:
At least 1 measurable site of disease ≥ 2 cm by radiography
Evaluable disease that could be reliably and consistently followed, as deemed by the principal investigator
RAAG12 expression confirmed* by immunohistochemistry NOTE: *Not required for patients with colon, pancreatic, or gastric adenocarcinoma
No evidence of residual or recurrent CNS metastases
Hormone receptor status:
Not specified
PATIENT CHARACTERISTICS:
Age
18 and over
Sex
Not specified
Menopausal status
Not specified
Performance status
ECOG 0-1
Life expectancy
More than 3 months
Hematopoietic
Platelet count ≥ 100,000/mm^3
Hemoglobin ≥ 9.0 g/dL (transfusions allowed)
Absolute neutrophil count ≥ 1,500/mm^3
Hepatic
Bilirubin ≤ 1.5 times upper limit of normal (ULN)
AST and ALT ≤ 2.5 times ULN
Alkaline phosphatase ≤ 2.5 times ULN
γ-glutamyl transferase ≤ 2.5 times ULN
Adequate hepatic function sufficient to undergo study therapy
Renal
Creatinine < 1.5 mg/dL
Adequate renal function sufficient to undergo study therapy
Cardiovascular
No New York Heart Association class III or IV heart disease
No thrombosis within the past 3 months, including any of the following:
Deep vein thrombosis
Myocardial infarction
Stroke
Adequate cardiac function sufficient to undergo study therapy
Pulmonary
No pulmonary embolism within the past 3 months
No significant pulmonary compromise, particularly dependence on supplemental oxygen on an as-needed or continuous basis
Adequate pulmonary function sufficient to undergo study therapy
Immunologic
No active viral, bacterial or systemic fungal infection requiring parenteral therapy within the past 4 weeks
No history of chronic or recurrent infection requiring continual antiviral, antifungal, or antibacterial agents
No known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in study drug
Other
Amylase and lipase normal
No other primary malignancy within the past 3 years except for the following:
Treated non-melanoma skin cancer
Carcinoma in situ of the cervix by biopsy
Squamous intraepithelial lesion of the cervix by PAP smear
Localized prostate cancer (Gleason score < 6)
Resected melanoma in situ
No other serious medical condition that would preclude study participation
No dementia or altered mental status that would preclude giving informed consent
Not pregnant or nursing
Negative pregnancy test
Fertile patients must use effective contraception during and for 3 months after study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy
At least 3 half-lives since prior monoclonal antibody therapy
No concurrent vaccinations
No concurrent prophylactic hematologic growth factors
Chemotherapy
At least 4 weeks since prior chemotherapy
Endocrine therapy
No concurrent steroids except for the following:
Inhaled, ophthalmic, or nasal steroids
Stable dose of oral prednisone (or equivalent) ≤ 10 mg/day
Radiotherapy
At least 4 weeks since prior radiotherapy
Surgery
More than 4 weeks since prior major surgery
Other
More than 4 weeks since prior investigational agents
Prior oral antiviral, antifungal, or antibacterial therapy allowed provided therapy was completed within the past week
No other concurrent antineoplastic therapy
No concurrent immunosuppressive medications
No other concurrent investigational agents
No concurrent vitamins except those approved by the medical monitor
Concurrent daily multivitamin allowed
Concurrent bisphosphonates allowed provided patient is on stable dose for ≥ 1 month prior to study entry
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 5 Locations for this study
Santa Monica California, 90404, United States
Washington District of Columbia, 20007, United States
Miami Florida, 33136, United States
Philadelphia Pennsylvania, 19111, United States
Nashville Tennessee, 37203, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.